Exclusive Online Content
Ferring Acquires Innovative Biotechnology Company and Microbiome Pioneer Rebiotix Inc.
Ferring Pharmaceuticals* and Rebiotix Inc. recently announced that they have agreed to the acquisition of Rebiotix by Ferring. This acquisition brings together two innovative healthcare…
Boehringer Ingelheim & OSE Immunotherapeutics Announce Global Immuno-Oncology Partnership
Boehringer Ingelheim and OSE Immunotherapeutics recently announced a collaboration and exclusive worldwide collaboration and license agreement to jointly develop OSE-172, a SIRP-alpha antagonist targeting myeloid…
BioStem Technologies Announces Letter of Intent With CCM Pharma Solutions
BioStem Technologies, Inc. recently announced it has signed a Letter of Intent with CCM Pharma Solutions. CCM has identified several drugs in the cardiovascular, metabolic…
RedShiftBio Announces Collaboration Trial Completion
RedShift BioAnalytics, Inc. (RedShiftBio), a provider of analytical instrumentation for the characterization of protein therapeutics, recently announced the completion of Phase II of the company’s…
ERT Launches Phase I Site Certification Program to Improve Efficiencies in Clinical Development
ERT, a global data and technology company that minimizes uncertainty and risk in clinical trials, recently announced it has launched a certification program for Phase…
Helsinn Group Announces First Patient Enrolled in Phase 3b Study of NEPA IV Versus NEPA Oral
Helsinn recently announced that the first patient has been enrolled in a Phase 3b study to assess the safety and tolerability of IV NEPA fixed…
SELLAS Life Sciences Group Announces Notice of Allowance From US PTO for New Patent Covering Composition of Matter for WT-1 Peptides
SELLAS Life Sciences Group, Inc. recently announced that the US PTO issued a Notice of Allowance for US Patent Application No. 14/760,997 related to certain Wilms Tumor 1 (WT1) peptides.
Jupiter Orphan Therapeutics Announces IND Submission for Mucopolysaccharidosis Type-I
Jupiter Orphan Therapeutics, Inc. recently announced it had submitted its IND to the FDA on March 12, 2018 for Mucopolysaccharidosis Type-I (MPSI). This will be the first of several anticipated IND submissions in 2018 utilizing JOT’s platform product,JOTROL.
Majority of Clinical Trials Planned in 2018 Belong to Oncology
Cancer is one of the leading causes of morbidity and mortality across the world. Not surprisingly, oncology is going to be the top therapy areafor clinical trialsplanned to be initiated in 2018…
Evotec & Sanofi to Create an Evotec-Led Infectious Disease Open Innovation R&D Platform
Evotec AG and Sanofi have entered into exclusive negotiations for Evotec to accelerate infectious disease research and development through a new open innovation platform near Lyon, France.
BC Platforms Launches End-to-End Solution for Precision Medicine Powered by the Microsoft Genomics Service
BC Platforms, a pioneer in genomic data management and analytics, recently announced it has launchedGeneVision, a new end-to-end Solution for Precision Medicine, that uses theMicrosoft Genomics service which runs on Microsoft Azure.
Vividion Therapeutics Announces Strategic Research Collaboration With Celgene; $101 Million Up-Front Payment
Vividion Therapeutics, Inc., a biotechnology company using revolutionary proteomics and chemistry platforms,recently announced a strategic research collaboration with Celgene Corporation. The multi-year collaboration is focused…
Aduro Announces Development Milestone Achieved Under Merck Collaboration
Aduro Biotech, Inc. recently announced that the company earned a $3-million development milestone payment under its worldwide licensing agreement with Merck…
ProJect Pharmaceutics Expands Facilities for Formulation & Lyophilization Process Development
ProJect Pharmaceutics(PJP), specialized in formulation and process development for parenteral drug products, announces that it has extended its safety facilities by laboratories dedicated to handle GMO S2 and BSL-2 based biological products such as live virus vaccines…
Fierce Competition Amongst Checkpoint Inhibitor Developers Ahead
Over the next ten years, PD-(L)1 inhibitors will continue to dominate the checkpoint modulators market, says leading data and analytics companyGlobalData.
Catalent Completes Multi-Million Expansion at Singapore Clinical Supply Facility
Catalent Pharma Solutions, the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced the completion of a two-year, $4.6 million…
SELLAS Life Sciences Group Announces Notice of Allowance From US PTO for New Patent Covering Composition of Matter for WT-1 Peptides
SELLAS Life Sciences Group, Inc. recently announced that the US PTO issued a Notice of Allowance for US Patent Application No. 14/760,997 related to certain…
Jupiter Orphan Therapeutics Announces IND Submission for Mucopolysaccharidosis Type-I
Jupiter Orphan Therapeutics, Inc. recently announced it had submitted its IND to the FDA on March 12, 2018 for Mucopolysaccharidosis Type-I (MPSI). This will be…
Majority of Clinical Trials Planned in 2018 Belong to Oncology
Cancer is one of the leading causes of morbidity and mortality across the world. Not surprisingly, oncology is going to be the top therapy area…
Evotec & Sanofi to Create an Evotec-Led Infectious Disease Open Innovation R&D Platform
Evotec AG and Sanofi have entered into exclusive negotiations for Evotec to accelerate infectious disease research and development through a new open innovation platform near…
